Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 8Triple Negative Breast Neoplasms 7Nasopharyngeal Carcinoma 7Breast Neoplasms 6Esophageal Neoplasms 4Colorectal Neoplasms 4Uterine Cervical Neoplasms 3Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Pancreatic Neoplasms 3Liver Neoplasms 3Neoplasm Metastasis 2Locally Advanced Rectal Cancer 2Carcinoma, Non-Small-Cell Lung 2Adrenocortical Carcinoma 2Unresectable Gallbladder Cancer 1Turcot syndrome 1Sarcoma 1Salivary Gland Neoplasms 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Non Squamous Non Small Cell Lung Cancer 1Nasopharyngeal Neoplasms 1Multiple Primary Lung Cancer 1Melanoma 1Locally Advanced or Metastatic Solid Tumors 1Liver Diseases 1Leukemia, Myeloid, Acute 1Her-2 Negative Breast Cancer 1

Interventions

Bevacizumab 4Paclitaxel 2Lutetium-177 2Lutetium 2ribociclib 1repotrectinib 1regorafenib 1pembrolizumab 1palbociclib 1olaparib 1lutetium Lu 177 dotatate 1copper dotatate CU-64 1camrelizumab 1atezolizumab 1apatinib 1Tretinoin 1Radiation 1Propranolol 1Leucovorin 1Irinotecan 1Imatinib Mesylate 1Hyperthermic Intraperitoneal Chemotherapy 1Fulvestrant 1Fluorouracil 1Drug Therapy 1Clinical Trials, Phase II as Topic 1Cisplatin 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Digestive System Neoplasms × camrelizumab × Clear all
NCT05624099 2023-10-19

Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.

Fujian Cancer Hospital

Phase 2 Recruiting
75 enrolled
Gastrointestinal

Digestive System Neoplasms, Esophageal Diseases, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡